A 10 mg semaglutide vial contains lyophilized (freeze-dried) powder, a white to off-white cake or powder sitting at the bottom of the vial
A second study reports that GLP-1 use may be associated with an increased risk for osteoporosis, gout, and osteomalacia in people with type 2 diabetes and obesity
Aetna, a private insurance company, may cover Wegovy under specific conditions if you are obese (BMI of 30 or more) or overweight (BMI of 27 or more)
GLP-1 therapy may be ideal if you: Have struggled with long-term weight gain Have a BMI over 27 with weight-related health conditions Experience insulin resistance, prediabetes, or metabolic dysfunction Are seeking a medically monitored, non-surgical option for weight loss Our GLP-1 specialist Monica LoVerdi, FNP will evaluate your health history, goals, and lab results to determine if GLP-1 therapy is a safe and effective choice for you
Unlike many peptides that are fragile outside physiological conditions, BPC-157 is notable for its stability in the gastric environment a property that has made it a subject of sustained research interest